Dr. Steven Grinspoon is a recognized authority on metabolic and neuroendocrine dysregulation of visceral adiposity. More broadly, Dr. Grinspoon is recognized for his contributions to the understanding of abnormal fat distribution, and the resultant metabolic and inflammatory changes in lipodystrophy.

Dr. Grinspoon's work investigates the nutritional regulation of pituitary function and encompasses a broad focus including the mechanism by which fat regulates neuroendocrine function, the mechanisms of insulin resistance in fat redistribution and acquired lipodystrophy and the role of altered nutrient trafficking in visceral obesity.

Dr. Grinspoon has served to Chair the Department of Health and Human Services Working Group on HIV and Wasting as well as on the World Health Organization, Technical Advisory Group on Nutrition and HIV/AIDS. He Co-Chaired the Research Affairs Committee for the Endocrine Society and Directed the Endocrine Society’s Clinical Investigators Workshop. He chaired the AHA State of the Science Conference on Cardiovascular Disease in HIV. His current research has linked increased arterial inflammation to CVD risk and monocyte activation in HIV. With respect to studies of adiposity, he has investigated the effects of blocking TNF in generalized obesity and use of hypothalamic peptides, including GHRH, to selectively reduce visceral fat. His efforts led to the FDA approval in November 2010 of GHRH as the first therapy to reduce visceral fat in HIV lipodystrophy.

Dr. Grinspoon has been highly successful as a clinical investigator and mentor to numerous researchers and is the Director of the MGH Program in Nutritional Metabolism. He is the PI on a Harvard wide NIH Training Grant in Nutrition and Metabolism.